medigraphic.com

2021, Number 3

<< Back Next >>

Enf Infec Microbiol 2021; 41 (3)

Bacterial resistance: organisms of the ESKAPE group

Guevara DJA, Rojas MM, Valadez PDE, Muro DR, Matsumoto PIR

Language: Spanish
References: 34
Page: 111-117
PDF size: 222.08 Kb.


ABSTRACT

Carry out a bibliographic analysis on current publications related to the ESKAPE group of bacteria.
Methods. Metasearch engines were searched with a combination of keywords. The search was updated on December 2, 2020. A search period for published/disclosed documents was established from January 1, 2000 to November 10, 2020 and only texts in Spanish or English were accepted. We also hand searched the bibliographies of included studies for further ancillary research.
Conclusions. There is an urgent need to take action to stay at the forefront of the growing drug-resistant ESKAPE pathogens. Therefore, it is essential to keep health personnel informed about the pathogenesis and basic characteristics of these organisms, so that they are approached with the most optimal treatments.


REFERENCES

  1. Organización Panamericana de la Salud (ops), “Prevención y control de la resistencia a los antimicrobianos en las Américas. Plan estratégico de vigilancia de la resistencia a los antibióticos”, ops/hcp/hct/139/99. Disponible en: http://www.paho.org/Spanish/HCP/HCT/EER/Plan- RegionalParaguay.doc.

  2. Mulani, M.S., Kamble, E.E., Kumkar, S.N., Tawre, M.S. y Pardesi, K.R., “Emerging strategies to combat eskape pathogens in the era of antimicrobial resistance: a review”, Front Microbiol, 2019, 10: 1-24.

  3. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L. y Ouellette, M., “Descubrimiento, investigación y desarrollo de nuevos antibióticos: la lista de prioridades de la oms de bacterias resistentes a los antibióticos y tuberculosis”, Lancet Infect Dis, 2018, 18 (3): 318-327.

  4. “Informe anual de la Red Hospitalaria de Vigilancia Epidemiológica”, 2015. Disponible en: https://www.gob. mx/cms/uploads/attachment/file/212974/infoanual_rhove_ 2015.pdf.

  5. Garza-González, E., Morfín-Otero, R., Mendoza-Olazarán, S., Bocanegra-Ibarias, P., Flores-Treviño, S., Rodríguez-Noriega, E. et al., “A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period”, plos One, 2019, 14: e0209865.

  6. Santajit, S. e Indrawattana, N., “Mechanisms of antimicrobial resistance in eskape pathogens”, Biomed Res Int, 2016, 2475067.

  7. Munita, J.M. y Arias, C.A., “Mechanisms of antibiotic resistance”, Microbiol Spectrum, 2016, 4 (2): vmbf- 0016-2015.

  8. Quiñones Pérez, D., “Resistencia antimicrobiana: evolución y perspectivas actuales ante el enfoque ‘Una salud’”, Rev Cubana Med Trop, 2017, 69 (3): 1-17.

  9. Centros para el Control y la Prevención de Enfermedades- Oficina de Enfermedades Infecciosas, “Amenazas de resistencia a los antibióticos en los Estados Unidos, 2013”, abril de 2013. Disponible en: http://www.cdc. gov/drugresistance/threat-report-2013.

  10. Ventola, C.L., “La crisis de la resistencia a los antibióticos. Parte 1: causas y amenazas”, p & t, revista revisada por pares para la gestión de formularios, 2015, 40 (4), 277-283.

  11. Sengupta, S., Chattopadhyay, M.K. y Grossart, H.P., “Las funciones multifacéticas de los antibióticos y la resistencia a los antibióticos en la naturaleza”, Fronteras en Microbiología, 2013, 4: 47.

  12. Spellberg, B. y Gilbert, D.N., “The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett”, Clinical Infectious Dis, 2014, 59 (Suppl 2), s71-s75.

  13. Centers for Disease Control and Prevention, “How do germs become resistant?”, Disponible en: https:// www.cdc.gov/drugresistance/about/how-resistance-happens. html.

  14. Guzmán Prieto, A.M., Van Schaik, W., Rogers, M.R., Coque, T.M., Baquero, F., Corander, J. y Willems, R.J., “Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones?”, Frontiers Microbiol, 2016, 7: 788.

  15. Lopardo, H., “La resistencia a vancomicina más allá de los enterococos”, Medicina Infantil, 2016, 2 3(4), 303-307.

  16. Díaz Pérez, M., Rodríguez Martínez, C. y Zhurbenko, R., “Aspectos fundamentales sobre el género Enterococcus como patógeno de elevada importancia en la actualidad”, Revista Cubana de Higiene y Epidemiología, 2010, 48 (2): 147-161.

  17. Raza, T., Ullah, S.R., Mehmood, K. y Andleeb, S., “Vancomycin resistant Enterococci: a brief review”, J Pak Med Assoc, 2018, 68 (5): 768-772.

  18. Ortega González, L.M., “Enterococos: actualización”, Revista Habanera de Ciencias Médicas, 2010, 9 (4), 507-515.

  19. Lee, A.S., De Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A. y Harbarth, S., “Methicillin- resistant Staphylococcus aureus”, Nature Reviews Disease Primers, 2018; 4: 18033. Disponible en: https:// doi.org/10.1038/nrdp.2018.33.

  20. Dayan, G.H., Mohamed, N., Scully, I.L., Cooper, D., Begier, E., Eiden, J., Jansen, K.U., Gurtman, A. y Anderson, A.S., “Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention”, Exp Rev Vaccines, 2016, 15 (11): 1373-1392.

  21. David, M.Z. y Daum, R.S., “Treatment of Staphylococcus aureus infections”, Curr Topics Microbiol Immunol, 2017, 409: 325-383.

  22. Deurenberg, R.H. y Stobberingh, E.E., “The evolution of Staphylococcus aureus”, Infect Genet Evol, 2008 8 (6): 747-763.

  23. Vargas, J.A. y Echeverri-Toro, L.M., “K. pneumoniae: ¿the new ‘superbacteria’? Pathogenicity, epidemiology and resistance mechanisms”, Iatreia, 2010, 23 (2):157-165.

  24. Echeverri, L. y Cataño, J., “Klebsiella pneumoniae como patógeno intrahospitalario: epidemiología y resistenEcheverri- Toro, L.M., Rueda, Z.V., Maya, W., Agudelo, Y.

  25. y Ospina, S., “Klebsiella pneumoniae multirresistente, factores predisponentes y mortalidad asociada en un hospital universitario en Colombia”, Rev Chil Infectol, 2012, 29 (2):175-182.

  26. García, T., Castillo, A. y Salazar, D., “Mecanismos de resistencia a betalactámicos en bacterias gram negativas”, Rev Cuba Salud Publica, 2014, 40 (1): 8.

  27. Howard, A., O’Donoghue, M., Feeney, A. y Sleator, R.D., “Acinetobacter baumannii. An emerging opportunistic pathogen”, Virulence, 2012, 3 (3): 5.

  28. López, S.L. y Brea, M., “¿Qué debemos saber acerca de las infecciones por Acinetobacter baumanii”, Enferm Infecc Microbiol Clin, 2000, 18 (3): 153-156.

  29. Rosenbaum, P., Aureden, K., Cloughessy, M., Goss, L., Kassai, M., Streed, S.A., Patrick, M.R., Von Behren, S. y Wrigth, M.O., “Guide to the elimination of multidrug-resistant Acinetobacter baumannii transmission in healthcare settings”, An apic Guide, 2010.

  30. Magalhães, B., Valot, B., Abdelbary, M.M., Proud’hom, G., Greub, G., Senn, L. y Blanc, D.S., “Combining standard molecular typing and whole genome sequencing to investigate Pseudomonas aeruginosa epidemiology in intensive care units”, Frontiers in Public Health, 2020, 28, 8:3.

  31. Horcajada, J.P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N. y Grau, S., “Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections”, Clinical Microbiology Reviews, 2019, 32 (4).

  32. Pena, C., Cabot, G., Gómez-Zorrilla, S., Zamorano, L., Ocampo-Sosa, A., Murillas, J. et al., “Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections”, Clinical Infectious Diseases, 2014, 60 (4): 539-548.

  33. Thaden, J.T., Pogue, J.M. y Kaye, K.S., “Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae”, Virulence, 2017, 8 (4): 403-416. doi:10.1080/2150 5594.2016.1207834.

  34. Lopardo, H., Predari, S. y Vay, C., Manual de microbiología clínica de la Asociación Argentina de Microbiología, Buenos Aires, Porrúa, 2013.




2020     |     www.medigraphic.com